From Diabetes to Liver Disease: The Expanding Role of GLP-1 Receptor Agonists
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are revolutionizing the management of metabolic diseases, offering powerful benefits that extend far beyond glucose control. Originally developed for type 2 diabetes, GLP-1RAs have demonstrated significant advantages in promoting weight loss, reducing cardiovascular risk, and now, treating liver conditions such as metabolic dysfunction-associated steatohepatitis (MASH). Backed by robust clinical […]
LinkPeptide